Integrated Chinese and Western Medicine for Coronary Heart Disease Prevention in Polycystic Ovary Syndrome: A 19-Year Nationwide Cohort Study

References

• The Lancet Regional H-E. Polycystic ovary syndrome: what more can be done for patients? Lancet Reg Health Eur. 2022;21:100524. doi:10.1016/j.lanepe.2022.100524
   PubMedGoogle Scholar
• Harada M. Pathophysiology of polycystic ovary syndrome revisited: current understanding and perspectives regarding future research. Reprod Med Biol. 2022;21(1):e12487. doi:10.1002/rmb2.12487
   PubMed Web of Science ®Google Scholar
• Sangaraju SL, Yepez D, Grandes XA, et al. Cardio-metabolic disease and Polycystic Ovarian Syndrome (PCOS): a narrative review. Cureus. 2022;14(5):e25076. doi:10.7759/cureus.25076
   PubMed Web of Science ®Google Scholar
• Rojas J, Chávez M, Olivar L, et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014;2014:719050. doi:10.1155/2014/719050
   PubMedGoogle Scholar
• Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013;56(3):137–142. doi:10.5468/ogs.2013.56.3.137
   PubMedGoogle Scholar
• Kim C, Schreiner PJ, Siscovick D, et al. Factors associated with self-report of polycystic ovary syndrome in the Coronary Artery Risk Development in Young Adults study (CARDIA). BMC Womens Health. 2023;23(1):248. doi:10.1186/s12905-023-02394-0
   PubMed Web of Science ®Google Scholar
• Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995;15(7):821–826. doi:10.1161/01.atv.15.7.821
   PubMed Web of Science ®Google Scholar
• Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481–3488. doi:10.1161/circulationaha.105.537878
   PubMed Web of Science ®Google Scholar
• Ralapanawa U, Sivakanesan R. Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health. 2021;11(2):169–177. doi:10.2991/jegh.k.201217.001
   PubMed Web of Science ®Google Scholar
• Ollila MM, Arffman RK, Korhonen E, et al. Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria-a prospective population-based cohort study. Eur J Endocrinol. 2023;189(1):96–105. doi:10.1093/ejendo/lvad077
   PubMed Web of Science ®Google Scholar
• Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30(7):399–404. doi:10.1016/j.tcm.2019.08.010
   PubMed Web of Science ®Google Scholar
• Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(6):942–960. doi:10.1093/humupd/dmaa029
   PubMed Web of Science ®Google Scholar
• Teede HJ, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine. 2006;30(1):45–53. doi:10.1385/ENDO:30:1:
   PubMed Web of Science ®Google Scholar
• Lo JC, Feigenbaum SL, Yang J, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(4):1357–1363. doi:10.1210/jc.2005-2430
   PubMed Web of Science ®Google Scholar
• Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;80(1):123–127. doi:10.1016/s0015-0282(03)00571-5
   PubMed Web of Science ®Google Scholar
• Aboeldalyl S, James C, Seyam E, et al. The role of chronic inflammation in polycystic ovarian syndrome-a systematic review and meta-analysis. Int J Mol Sci. 2021;22(5):2734. doi:10.3390/ijms22052734
   PubMed Web of Science ®Google Scholar
• Rudnicka E, Suchta K, Grymowicz M, et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22(7):3789. doi:10.3390/ijms22073789
   PubMed Web of Science ®Google Scholar
• Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf. 2009;4(3):209–228. doi:10.2174/157488609789006949
   PubMedGoogle Scholar
• Wake M, Oh A, Onishi Y, et al. Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan. Atherosclerosis. 2019;282:19–28. doi:10.1016/j.atherosclerosis.2018.12.026
   PubMed Web of Science ®Google Scholar
• Razavi-Nematollahi L, Ismail-Beigi F. Adverse effects of glycemia-lowering medications in type 2 diabetes. Curr Diab Rep. 2019;19(11):132. doi:10.1007/s11892-019-1266-7
   PubMed Web of Science ®Google Scholar
• Shaito A, Thuan DTB, Phu HT, et al. Herbal medicine for cardiovascular diseases: efficacy, mechanisms, and safety. Front Pharmacol. 2020;11:422. doi:10.3389/fphar.2020.00422
   PubMed Web of Science ®Google Scholar
• Kumar G, Dey SK, Kundu S. Herbs and their bioactive ingredients in cardio-protection: underlying molecular mechanisms and evidences from clinical studies. Phytomedicine. 2021;92:153753. doi:10.1016/j.phymed.2021.153753
   PubMed Web of Science ®Google Scholar
• Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prev Cardiol. 2000;3(1):24–32. doi:10.1111/j.1520-037x.2000.80355.x
   PubMedGoogle Scholar
• Pan X, Liu Y, Liu L, et al. Bushen Jieyu Tiaochong Formula reduces apoptosis of granulosa cells via the PERK-ATF4-CHOP signaling pathway in a rat model of polycystic ovary syndrome with chronic stress. J Ethnopharmacol. 2022;292:114923. doi:10.1016/j.jep.2021.114923
   PubMed Web of Science ®Google Scholar
• Pan X, Gu Y, Zhang X, et al. Chinese herbal medicine (Bu-Shen-Tian-Jing Formula) for outcomes of IVF in Chinese patients with polycystic ovary syndrome: a retrospective cohort study. Integr Med Res. 2022;11(1):100775. doi:10.1016/j.imr.2021.100775
   PubMed Web of Science ®Google Scholar
• Dwivedi AK, Vishwakarma D, Dubey P, Reddy S. Association of polycystic ovary syndrome with cardiovascular disease among female hospitalizations in the United States. Eur J Endocrinol. 2023;188(6):555–563. doi:10.1093/ejendo/lvad067
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol. 2000;52(5):595–600. doi:10.1046/j.1365-2265.2000.01000.x
   PubMed Web of Science ®Google Scholar
• Posadzki P, Lee MS, Moon TW, et al. Prevalence of complementary and alternative medicine (CAM) use by menopausal women: a systematic review of surveys. Maturitas. 2013;75(1):34–43. doi:10.1016/j.maturitas.2013.02.005
   PubMed Web of Science ®Google Scholar
• Nazik E, Nazik H, Api M, et al. Complementary and alternative medicine use by gynecologic oncology patients in Turkey. Asian Pac J Cancer Prev. 2012;13(1):21–25. doi:10.7314/apjcp.2012.13.1.021
   PubMedGoogle Scholar
• Lin YR, Wu MY, Chiang JH, et al. The utilization of traditional Chinese medicine in patients with dysfunctional uterine bleeding in Taiwan: a nationwide population-based study. BMC Complement Altern Med. 2017;17(1):427. doi:10.1186/s12906-017-1939-1
   PubMedGoogle Scholar
• Yang XC, Liu Y, Sun WW, et al. Efficacy of Chinese herbal medicines on pregnancy outcomes in patients with endometriosis in long-term management: a Multicenter Retrospective Cohort Study. Chin J Integr Med. 2023;29(11):971–979. doi:10.1007/s11655-023-3736-z
   PubMed Web of Science ®Google Scholar
• Zhao RH, Liu Y, Tan Y, et al. Chinese medicine improves postoperative quality of life in endometriosis patients: a randomized controlled trial. Chin J Integr Med. 2013;19(1):15–21. doi:10.1007/s11655-012-1196-6
   PubMed Web of Science ®Google Scholar
• Liao WT, Chiang JH, Li CJ, et al. Investigation on the use of traditional Chinese medicine for polycystic ovary syndrome in a nationwide prescription database in Taiwan. J Clin Med. 2018;7(7):179. doi:10.3390/jcm7070179
   PubMed Web of Science ®Google Scholar
• Zhu P, Guan JZ, Hai QC, et al. The clinical effectiveness and safety of traditional Chinese medicine Jinfeng pill in adjuvant treatment of infertility with polycystic ovary syndrome: a protocol for systematic review and meta-analysis. Medicine. 2022;101(4):e28676. doi:10.1097/md.0000000000028676
   PubMed Web of Science ®Google Scholar
• Wang L, Liang R, Tang Q, Zhu L. An overview of systematic reviews of using Chinese medicine to treat polycystic ovary syndrome. Evid Based Complement Alternat Med. 2021;2021:9935536. doi:10.1155/2021/9935536
   PubMed Web of Science ®Google Scholar
• Chen H, Deng C, Meng Z, Meng S. Effects of TCM on polycystic ovary syndrome and its cellular endocrine mechanism. Front Endocrinol. 2023;14:956772. doi:10.3389/fendo.2023.956772
   PubMed Web of Science ®Google Scholar
• Luo L, Shen Y, Ning D, et al. Chao Nang Qing prescription promotes granulosa cell apoptosis and autophagy by targeting GATA3. Gynecol Endocrinol. 2023;39(1):2223724. doi:10.1080/09513590.2023.2223724
   PubMedGoogle Scholar
• Liao WT, Su CC, Lee MT, et al. Integrative Chinese herbal medicine therapy reduced the risk of type 2 diabetes mellitus in patients with polycystic ovary syndrome: a nationwide matched cohort study. J Ethnopharmacol. 2019;243:112091. doi:10.1016/j.jep.2019.112091
   PubMed Web of Science ®Google Scholar
• Yi W, Li X, Chen K, et al. Effects of Cangfu Daotan Decoction on obese polycystic ovary syndrome and its mechanism. Steroids. 2021;165:108740. doi:10.1016/j.steroids.2020.108740
   PubMed Web of Science ®Google Scholar
• Wu M, Liu H, Zhang J, et al. The mechanism of Leonuri Herba in improving polycystic ovary syndrome was analyzed based on network pharmacology and molecular docking. J Pharm Pharm Sci. 2023;26:11234. doi:10.3389/jpps.2023.11234
   PubMed Web of Science ®Google Scholar
• Hsieh SC, Lai JN, Lee CF, et al. The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiol Drug Saf. 2008;17(6):609–619. doi:10.1002/pds.1611
   PubMed Web of Science ®Google Scholar
• Chen LC, Tsao YT, Yen KY, et al. A pilot study comparing the clinical effects of Jia-Wey Shiau-Yau San, a traditional Chinese herbal prescription, and a continuous combined hormone replacement therapy in postmenopausal women with climacteric symptoms. Maturitas. 2003;44(1):55–62. doi:10.1016/s0378-5122(02)00314-6
   PubMed Web of Science ®Google Scholar
• Zhou X, Ma Q, Yan Z, et al. Efficacy and safety of Chinese patent medicine Xiao Yao San in polycystic ovary syndrome: a systematic review and meta-analysis. J Ethnopharmacol. 2023;313:116517. doi:10.1016/j.jep.2023.116517
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li Y, Liu M, et al. Guizhi Fuling Wan, Chinese herbal medicine, ameliorates insulin sensitivity in PCOS model rats with insulin resistance via remodeling intestinal homeostasis. Front Endocrinol (Lausanne). 2020;11:575. doi:10.3389/fendo.2020.00575
   PubMed Web of Science ®Google Scholar
• Wu P, Zhu Y, Li J, et al. Guizhi Fuling Wan inhibits autophagy of granulosa cells in polycystic ovary syndrome mice via H19/miR-29b-3p. Gynecol Endocrinol. 2023;39(1):2210232. doi:10.1080/09513590.2023.2210232
   PubMed Web of Science ®Google Scholar
• Duan B, Han L, Ming S, et al. Fuling-Guizhi herb pair in coronary heart disease: integrating network pharmacology and in vivo pharmacological evaluation. Evid Based Complement Alternat Med. 2020;2020:1489036. doi:10.1155/2020/1489036
   PubMed Web of Science ®Google Scholar